Interleukin 1 inhibition with anakinra in adult-onset still disease: A meta-analysis of its efficacy and safety

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 2345-2357

  Hong, Dongsheng ^a   Yang, Zhihai ^a   Han, Shuyin ^a   Liang, Xingguang ^a   Ma, Kuifen ^a   Zhang, Xingguo ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Adverse events; Anakinra; AoSD; Clinical and laboratory parameters; Efficacy; Interleukin 1 inhibitor

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ADULT ONSET STILL DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINLAND; GEOGRAPHIC DISTRIBUTION; GREECE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NORWAY; OBSERVATIONAL STUDY; RASH; REMISSION; REVIEW; SWEDEN; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URTICARIA; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; META ANALYSIS (TOPIC); STILL'S DISEASE, ADULT-ONSET;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; META-ANALYSIS AS TOPIC; STILL'S DISEASE, ADULT-ONSET;

EID: 84919386902     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S73428     Document Type: Review

References (9)

1. Lequerré T, Quartier P, Rosellini D, et al; Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFRE-MIP); Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302–308.
2. Nordström D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39(10):2008–2011.
3. Cavalli G, Franchini S, Berti A, et al. Efficacy and safety of biologic agents in adult-onset Still’s disease: A long-term follow-up of 19 patients at a single referral center [abstract]. Arthritis Rheum. 2013;65 Suppl 10:S2028.
4. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91–99.
5. Giampietro C, Ridene M, Lequerre T, et al; CRI (Club Rhumatismes et Inflammation). Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65(5):822–826.
6. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13(3):R91.
7. Iliou C, Papagoras C, Tsifetaki N, Voulgari PV, Drosos AA. Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31(1):47–52.
8. Giampietro C, Ridene M, Fautrel B, Bourgeois P. Long term treatment with anakinra in patients with adult-onset Still disease [abstract]. Arthritis Rheum. 2010;62 Suppl 10:S902.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009:6(7): e1000097. doi:10.1371/ journal.pmed.1000097.